Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Immune-based therapies for hepatocellular carcinoma.
Oncogene ( IF 6.9 ) Pub Date : 2020-03-10 , DOI: 10.1038/s41388-020-1249-9 David J Pinato 1 , Nadia Guerra 2 , Petros Fessas 1 , Ravindhi Murphy 1 , Takashi Mineo 3 , Francesco A Mauri 1 , Sujit K Mukherjee 4 , Mark Thursz 4 , Ching Ngar Wong 1 , Rohini Sharma 1 , Lorenza Rimassa 5, 6
Oncogene ( IF 6.9 ) Pub Date : 2020-03-10 , DOI: 10.1038/s41388-020-1249-9 David J Pinato 1 , Nadia Guerra 2 , Petros Fessas 1 , Ravindhi Murphy 1 , Takashi Mineo 3 , Francesco A Mauri 1 , Sujit K Mukherjee 4 , Mark Thursz 4 , Ching Ngar Wong 1 , Rohini Sharma 1 , Lorenza Rimassa 5, 6
Affiliation
|
Hepatocellular carcinoma (HCC) is the third most frequent cause of cancer-related death. The immune-rich contexture of the HCC microenvironment makes this tumour an appealing target for immune-based therapies. Here, we discuss how the functional characteristics of the liver microenvironment can potentially be harnessed for the treatment of HCC. We will review the evidence supporting a therapeutic role for vaccines, cell-based therapies and immune-checkpoint inhibitors and discuss the potential for patient stratification in an attempt to overcome the series of failures that has characterised drug development in this disease area.
中文翻译：
肝细胞癌的免疫疗法。
肝细胞癌 (HCC) 是癌症相关死亡的第三大常见原因。 HCC 微环境中富含免疫的环境使这种肿瘤成为基于免疫疗法的有吸引力的目标。在这里，我们讨论如何利用肝脏微环境的功能特征来治疗 HCC。我们将回顾支持疫苗、细胞疗法和免疫检查点抑制剂的治疗作用的证据，并讨论患者分层的潜力，以试图克服该疾病领域药物开发的一系列失败。
更新日期：2020-03-10
中文翻译：
肝细胞癌的免疫疗法。
肝细胞癌 (HCC) 是癌症相关死亡的第三大常见原因。 HCC 微环境中富含免疫的环境使这种肿瘤成为基于免疫疗法的有吸引力的目标。在这里，我们讨论如何利用肝脏微环境的功能特征来治疗 HCC。我们将回顾支持疫苗、细胞疗法和免疫检查点抑制剂的治疗作用的证据，并讨论患者分层的潜力，以试图克服该疾病领域药物开发的一系列失败。
京公网安备 11010802027423号